Navigation Links
Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN
Date:7/24/2014

New York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication of results from the long-term, randomized, active control Phase 3 study of Zerenex (ferric citrate), the Company's investigational oral ferric iron-based phosphate binder, for the treatment of hyperphosphatemia in patients with end-stage renal disease (ESRD) on dialysis. The PERFECTED study (PhosphatE binding and iRon delivery with FErric CiTrate in EsrD) was published online today in the Journal of the American Society of Nephrology (JASN).

This Phase 3 study was a multicenter, randomized, open-label trial in 441 ESRD patients on hemodialysis or peritoneal dialysis designed to determine the safety and efficacy of Zerenex as a treatment to reduce serum phosphorus as well as raise iron stores and reduce intravenous (IV) iron and erythropoietin-stimulating agents (ESA) usage.

Zerenex met the study's primary end-point demonstrating a highly statistically significant change in serum phosphorus versus placebo over the four-week Placebo Control Period. Using a sequential gatekeeping strategy for the key pre-defined secondary end-points, Zerenex also demonstrated statistically significant increases in serum ferritin and transferrin saturation (TSAT), and significant reductions in the use of IV iron and ESAs, versus an active control of Renvela (sevelamer carbonate) and/or Phoslo (calcium acetate) over the 52-week Active Control Period of the study. In addition, mean hemoglobin levels were higher in subjects treated with Zerenex as compared to subjects treated with active control.

"Zerenex effectively reduces serum phosphorus levels within the KDOQI range (3.5 mg/dL to 5.5 mg/dL) while having the additional patient benefits of increasing iron stores and decreasing the need for IV iron and ESAs, while maintaining hemoglobin levels," said Julia Lewis, MD, lead investigator, nephrologist and Professor of Medici
'/>"/>

Contact: Amy Sullivan
amy.sullivan@keryx.com
617-466-3447
Keryx Biopharmaceuticals, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related biology news :

1. Long-term childhood poverty contributes to young adult obesity rates
2. Study finds long-term survival of human neural stem cells transplanted into primate brain
3. Long-term predictions for Miami sea level rise could be available relatively soon
4. Swedish researchers show impact of long-term vitamin D insufficiency on fracture risk
5. Chemical spill activates Virginia Tech engineers in effort to determine long-term effects
6. To calculate long-term conservation pay off, factor in people
7. Long-term spinal cord stimulation stalls symptoms of Parkinsons-like disease
8. Fetal exposure to nicotine increases long-term risk of obesity
9. Miriam Hospital study shows keys to successful long-term weight loss maintenance
10. Gene therapy for human skin disease produces long-term benefits
11. Deep-sea corals record dramatic long-term shift in Pacific Ocean ecosystem
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/16/2014)... have challenged conventional thinking on how the bowel lining ... for how bowel cancer starts. , The researchers produced ... regenerating the ,crypts, that are a feature of the ... in bowel cancer development, a controversial finding as scientists ... Using 3D imaging technologies, Dr Chin Wee Tan and ...
(Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. (NASDAQ: ... "Company"), a biometric authentication company focused on the growing ... edge technologies including Wocket™, the Smart Wallet, at the ... FiRe is a leading global conference on the intersection ... by Mark Anderson , founder and publisher of ...
(Date:10/15/2014)... has admitted Johannes Gutenberg University Mainz (JGU) as ... hub continues to maintain a significant nationwide standing ... "The acceptance of Johannes Gutenberg University Mainz as ... milestone in the national and international competition for ... of Rhineland-Palatinate can be proud that Mainz University ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3
... West Indian tarantula has been shown to cause pain ... sense high temperatures and the hot, spicy ingredient in ... demonstrate that some plants and animals have evolved the ... by activating a specific receptor on sensory nerves. The ...
... gardener knows--different plant species mature at different times. ... this phenomenon "complementarity." It allows many species to ... period when species compete for limited resources. Now, ... Sept. 4 in the Proceedings of the National ...
... the limb regrows. What is more, a newt can also ... Planck Institute for Heart and Lung Research in Bad Nauheim ... impressive ability to regenerate and have discovered the remarkable plasticity ... do not have this ability, the findings could contribute to ...
Cached Biology News:Tarantula venom and chili peppers target same pain sensor 2Global changes alter the timing of plant growth, scientists say 2Global changes alter the timing of plant growth, scientists say 3Newts which regrow their hearts 2
(Date:10/22/2014)... , Oct. 22, 2014 New test innovations ... in vitro diagnostic (IVD) test industry, especially as companies ... market researcher listed more than 25 testing innovations in ... the future of IVD products. Kalorama details the new approaches ... Worldwide Market for In Vitro Diagnostic Tests , ...
(Date:10/22/2014)... 21, 2014 Shimadzu Scientific Instruments introduces ... tool for the pain management and clinical markets. The ... and review by allowing users to highlight and review ... , QuantAnalytics allows analysts to filter results by group ... processing by eliminating the need to sift through analytes ...
(Date:10/22/2014)... SC (PRWEB) October 22, 2014 ... of its cardiovascular pharmacogenetics menu, which enables healthcare ... outcomes. With PCLS’s evidence-based results, healthcare providers ... and optimize their therapy, while minimizing risks for ... the U.S., according to the FDA [1] more ...
(Date:10/22/2014)... Oct. 22, 2014 Research and Markets ... Market by Material, by Application, Geography - Global Analysis ... offering. Organic electronics, also called as ... material science which deals with small conductive molecules and ... small molecules and polymers are carbon based, made using ...
Breaking Biology Technology:Report: Radical New IVD Test Approaches Key To Growth 2Report: Radical New IVD Test Approaches Key To Growth 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 2Global Organic Electronics (Semiconductor, Conductive, Dielectric and Substrate) Market - Analysis and Forecast (2014 - 2020) 3
... Switzerland, August 19 Arpida Ltd,(SIX: ARPN) announced today its financial results ... Key events 2009 to date, - Regulatory setback for ... under review, - Company restructuring completed, , ... June 2009 , CFO Harry Welten, MBA, commented: ...
... , WESTON, Fla., Aug. 19 In keeping with ... of families, America n Scientific Resources ... obtained from Safeguard Medical Technologies, LLC exclusive worldwide rights to sell ... and the Disintegrator Plus(TM). , , All ...
... , , LONDON, Aug. 19 ... the introduction of improved drugs to treat the disease. As healthcare ... companies conducting research on diabetes vaccines. If they succeed, the entire ... (Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) , , ...
Cached Biology Technology:Arpida Reports Interim Results For Six Months to 30 June 2009 2American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device 2American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device 3Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan 2Emergence of Newer Drug Classes to Treat Diabetes and Co-morbidities Key to Market Expansion, Reveals Frost & Sullivan 3
... fluorescein-conjugated jetSI-ENDO (excitation at ... nm), the powerful siRNA transfection ... to determine the transfection efficiency ... and trafficking of siRNAs. More ...
... of long double stranded RNA (dsRNA) has ... a diverse group of organisms as well ... leads to the inhibition of protein expression ... target messenger RNA (mRNA). Attempts to induce ...
... lower cost and reduced space requirements ... reference standard DNA analysis technology affordable ... with any of SEQUENOM's applications and ... (iPLEXTM Gold) , Gene Expression Analysis ...
... Bruker Daltonics and Bruker BioSpins Metabolic ... metabolism studies, and analysis of complex ... system, an optional Avance NMR spectrometer ... evaluation and statistical analysis for applications ...
Biology Products: